Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD)
Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD)
Highly active antiretroviral therapy (HAART) has considerably improved survival of
 HIV-infected patients. Opportunist diseases and cancers linked to immunodepression have
 largely regressed. Challenge is now the management of cardio-vascular diseases, nephrologic,
 neurologic, osteo-articular diseases, chronic hepatitis and cancer no linked to
 immunodepression. All this comorbidities are more reported in HIV-infected patients than in
 general non-HIV infected patients. Those are directly linked to the effect of chronic
 HIV-infection on ageing, metabolic effects of HAART, and way of life characterising this
 population.

 Chronic obstructive pulmonary disease (COPD) results from tobacco consumption. Bronchial
 chronic infection, immunity, and ageing are also involved in the physiopathology of COPD.
 This disease has never been evaluated in a large prospective cohort of HIV-infected patients
 whereas there is a known increase of tobacco consumption and pulmonary infection in this
 population regardless to the general population.

 Characterisation of COPD disease in HIV patients will allow us to make an hypothetic
 epidemiological link between HIV- HAART and COPD independently of tobacco consumption, and to
 study different physiopathologic hypothesis evocated in COPD genesis, like an accelerate
 pulmonary ageing.
The management of HIV is mainly represented by its commorbidities (cardio-vascular disease,
 nephrologic, neurologic, osteo-articular disease, chronic hepatitis and cancer no linked to
 immunodepression). COPD prevalence has never been studied in HIV population. In consequence,
 there is no guideline about the screening, treatment or follow-up of COPD in HIV patients.
 However this population seems particularly at risk to develop COPD because of high tobacco
 consumption and accelerate ageing. Thus, we need an epidemiologic study to understand the
 prevalence of COPD in HIV population in order to organize a specific screening and follow-up.
 This is supported by an improvement of COPD if early managed. On top of that, COPD screening
 will increase awareness of HIV patients on the problematic of tobacco consumption.
Inclusion criteria:

 -  HIV seropositivity

 -  Age > 18 years

 -  Written aggreeing

 -  Affiliated or profit of a social coverage

 Non inclusion criteria:

 -  Age < 18 years old

 -  Actual infectious pneumonia

 -  COPD exacerbation last 2 months *

 -  Recent (less than 1 month) myocardial infarction

 -  Thoracic or abdominal pain

 -  Enable to answer question secondary to mental deficienty**

 -  Physic or mental incapacity to realise COPD-6 or spirometery

 -  Urinary incontinency with effort

 -  Prisoner

 -  Refuse of consent or incapacity to give his consent